Yu LP, Li YJ, Wang T, Tao YX, Zhang M, Gu W, Yu J, Yang XX. In vivo recognition of bioactive substances of Polygonum multiflorum for protecting mitochondria against metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2023; 29(1): 171-189 [PMID: 36683716 DOI: 10.3748/wjg.v29.i1.171]
Corresponding Author of This Article
Xing-Xin Yang, PharmD, Professor, College of Pharmaceutical Science, Yunnan University of Chinese Medicine, No. 1076 Yuhua Road, Kunming 650500, Yunnan Province, China. yxx78945@163.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Yu LP, Li YJ, Wang T, Tao YX, Zhang M, Gu W, Yu J, Yang XX. In vivo recognition of bioactive substances of Polygonum multiflorum for protecting mitochondria against metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2023; 29(1): 171-189 [PMID: 36683716 DOI: 10.3748/wjg.v29.i1.171]
World J Gastroenterol. Jan 7, 2023; 29(1): 171-189 Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.171
In vivo recognition of bioactive substances of Polygonum multiflorum for protecting mitochondria against metabolic dysfunction-associated fatty liver disease
Li-Ping Yu, Yan-Juan Li, Tao Wang, Yu-Xuan Tao, Mei Zhang, Wen Gu, Jie Yu, Xing-Xin Yang
Li-Ping Yu, Yan-Juan Li, Tao Wang, Yu-Xuan Tao, Mei Zhang, Wen Gu, Jie Yu, Xing-Xin Yang, College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China
Li-Ping Yu, Yan-Juan Li, Tao Wang, Yu-Xuan Tao, Mei Zhang, Wen Gu, Jie Yu, Xing-Xin Yang, College of Pharmaceutical Science, Yunnan Key Laboratory of Southern Medicine Utilization, Kunming 650500, Yunnan Province, China
Author contributions: Yu LP, Li YJ, and Wang T contributed equally to this work; Li YJ wrote the manuscript; Li YJ, Yu LP, and Wang T performed the experiments; Tao YX and Zhang M provided technical support and suggestions; Yang XX, Yu LP, Zhang M, and Gu W participated in writing and modifying the manuscript; Yang XX and Yu J designed the study; and all authors approved the final manuscript.
Supported bythe National Natural Science Foundation of China, No. 82060707 and 82104381; the Application and Basis Research Project of Yunnan China, No. 202201AW070016, 202001AZ070001-006, and 2019IB009; and the Young and Middle-aged Academic and Technological Leader of Yunnan, No. 202005AC160059.
Institutional animal care and use committee statement: Approval was obtained from the Ethical Committee on Animal Care and Experimentation of the Yunnan University of Chinese Medicine (R-06201965).
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Data sharing statement: All data used to support the findings of this study are available from the corresponding author upon reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Corresponding author: Xing-Xin Yang, PharmD, Professor, College of Pharmaceutical Science, Yunnan University of Chinese Medicine, No. 1076 Yuhua Road, Kunming 650500, Yunnan Province, China. yxx78945@163.com
Received: September 7, 2022 Peer-review started: September 7, 2022 First decision: October 19, 2022 Revised: November 1, 2022 Accepted: December 5, 2022 Article in press: December 5, 2022 Published online: January 7, 2023 Processing time: 118 Days and 22.4 Hours
Core Tip
Core Tip: We found that Polygonum multiflorum (PM) protected the mitochondrial ultrastructure and prevented oxidative stress and energy production disorder in the liver mitochondria to mitigate metabolic dysfunction-associated fatty liver disease (MAFLD). Eight chemicals were identified from the liver mitochondria of the PM-treated rats using a novel strategy based on mitochondrial pharmacology and pharmacochemistry. The constituents identified regulated mitochondria to alleviate MAFLD. Our results indicate that PM restored mitochondrial structure and function and alleviated MAFLD, which may be related to oxidative stress and energy production. The eight substances may be the main pharmacodynamic ingredients in PM that regulate mitochondria to prevent MAFLD.
